Literature DB >> 21778247

Mesial prefrontal cortex degeneration in amyotrophic lateral sclerosis: a high-field proton MR spectroscopy study.

U Usman1, C Choi, R Camicioli, P Seres, M Lynch, R Sekhon, W Johnston, S Kalra.   

Abstract

BACKGROUND AND
PURPOSE: Frontotemporal lobar degeneration is responsible for the cognitive abnormalities seen in patients with ALS. We sought to evaluate the in vivo neurochemical changes associated with this pathology indicative of neuronal loss and gliosis.
MATERIALS AND METHODS: Twenty-four patients with ALS (2 with ALS-FTD) and 15 healthy controls were studied. High-field proton MR spectroscopy of the mesial prefrontal cortex was used to determine concentrations of NAA and mIns, markers of neuronal integrity and gliosis, respectively. Metabolite concentrations were correlated with cognitive tests (verbal fluency, ACE).
RESULTS: NAA/mIns was decreased 17% (P =.002). Abnormalities were present to a lesser degree in the individual metabolites NAA (decreased 9%; P =.08) and mIns (increased 11%; P =.06) than the ratio of the 2 metabolites. These measures did not correlate significantly with verbal fluency or the ACE.
CONCLUSIONS: Prefrontal lobe degeneration exists in patients with ALS as indicated by an abnormal mesial prefrontal cortex neurochemical profile. Further study is necessary to determine the potential utility of the NAA/mIns ratio as a biomarker for frontal lobe degeneration in ALS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778247      PMCID: PMC7965387          DOI: 10.3174/ajnr.A2590

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  36 in total

1.  Sources of variability in the response of coupled spins to the PRESS sequence and their potential impact on metabolite quantification.

Authors:  R B Thompson; P S Allen
Journal:  Magn Reson Med       Date:  1999-06       Impact factor: 4.668

2.  Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil.

Authors:  C M Lloyd; M P Richardson; D J Brooks; A Al-Chalabi; P N Leigh
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

3.  A neuropsychological investigation of dementia in motor neurone disease (MND).

Authors:  F P Barson; G J Kinsella; B Ong; S E Mathers
Journal:  J Neurol Sci       Date:  2000-11-01       Impact factor: 3.181

4.  Detection of the myo-inositol 4.06-ppm resonance by selective J rewinding: application to human prefrontal cortex in vivo.

Authors:  Changho Choi; Catherine J Ogilvie; Nikolai Malykhin; Jennifer T V Ngo; Misha A W Hartfeil; Nicholas J Coupland
Journal:  Magn Reson Med       Date:  2005-12       Impact factor: 4.668

5.  Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study.

Authors:  S Abrahams; L H Goldstein; J J Kew; D J Brooks; C M Lloyd; C D Frith; P N Leigh
Journal:  Brain       Date:  1996-12       Impact factor: 13.501

6.  Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS).

Authors:  S Abrahams; P N Leigh; A Harvey; G N Vythelingum; D Grisé; L H Goldstein
Journal:  Neuropsychologia       Date:  2000       Impact factor: 3.139

7.  Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy.

Authors:  Sanjay Kalra; Christopher C Hanstock; W R Wayne Martin; Peter S Allen; Wendy S Johnston
Journal:  Arch Neurol       Date:  2006-08

8.  Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS.

Authors:  W D Rooney; R G Miller; D Gelinas; N Schuff; A A Maudsley; M W Weiner
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

9.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra.

Authors:  S W Provencher
Journal:  Magn Reson Med       Date:  1993-12       Impact factor: 4.668

10.  Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis.

Authors:  Michael J Strong; Gloria M Grace; Morris Freedman; Cathy Lomen-Hoerth; Susan Woolley; Laura H Goldstein; Jennifer Murphy; Christen Shoesmith; Jeffery Rosenfeld; P Nigel Leigh; Lucie Bruijn; Paul Ince; Denise Figlewicz
Journal:  Amyotroph Lateral Scler       Date:  2009-06
View more
  5 in total

1.  Histological-MRI correlation in the primary motor cortex of patients with amyotrophic lateral sclerosis.

Authors:  Mark D Meadowcroft; Nathan J Mutic; Don C Bigler; Jian-Li Wang; Zachary Simmons; James R Connor; Qing X Yang
Journal:  J Magn Reson Imaging       Date:  2014-02-26       Impact factor: 4.813

Review 2.  25 years of neuroimaging in amyotrophic lateral sclerosis.

Authors:  Bradley R Foerster; Robert C Welsh; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2013-08-06       Impact factor: 42.937

3.  Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study.

Authors:  Daniel Ta; Abdullah Ishaque; Ojas Srivastava; Chris Hanstock; Peter Seres; Dean T Eurich; Collin Luk; Hannah Briemberg; Richard Frayne; Angela L Genge; Simon J Graham; Lawrence Korngut; Lorne Zinman; Sanjay Kalra
Journal:  Neurology       Date:  2021-06-14       Impact factor: 11.800

Review 4.  Clinical and Radiological Markers of Extra-Motor Deficits in Amyotrophic Lateral Sclerosis.

Authors:  Foteini Christidi; Efstratios Karavasilis; Michail Rentzos; Nikolaos Kelekis; Ioannis Evdokimidis; Peter Bede
Journal:  Front Neurol       Date:  2018-11-22       Impact factor: 4.003

5.  Cerebral degeneration in amyotrophic lateral sclerosis: A prospective multicenter magnetic resonance spectroscopy study.

Authors:  Ojas Srivastava; Chris Hanstock; Sneha Chenji; Dennell Mah; Dean Eurich; Daniel Ta; Peter Seres; Collin Luk; Lorne Zinman; Agessandro Abrahao; Simon J Graham; Angela Genge; Lawrence Korngut; Richard Frayne; Sanjay Kalra
Journal:  Neurol Clin Pract       Date:  2019-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.